Metabolon, Inc. Appoints Karl Bradshaw, Ph.D., to Lead Biopharma Strategy and Partnering: New role is integral to Metabolon’s growth strategy
Research Triangle Park, N.C. – October 8, 2019 – Metabolon, Inc., the global leader in revealing biological insights through metabolomics, announces the appointment of Karl Bradshaw, Ph.D., as Vice President of Biopharma Strategy and Partnering.
Dr. Bradshaw joins Metabolon from AstraZeneca, where he most recently served as Senior Director of Corporate Strategy and Development helping to advance business strategy through execution of mergers and acquisitions, divestitures and investments that bolstered core growth platforms and therapy areas. Dr. Bradshaw held several roles during his six-year tenure at AstraZeneca, including Head of Competitive Intelligence for infection, neuroscience and GI, and Business Development Director for AstraZeneca’s Antibiotics Business Unit. Prior to joining AstraZeneca, Dr. Bradshaw worked for seven years as Vice President of equity research at Morgan Stanley, where he gained extensive experience in financial analysis, modelling and valuation of biotech and medtech companies, as well as an excellent understanding of global healthcare sector trends and underlying market demographics.
Dr. Bradshaw earned his undergraduate degree in biological sciences from Birmingham University and a doctorate in neuroscience from University College London. He conducted postdoctoral work at the National Institute for Medical Research, later completing an MPhil in Bioscience Enterprise from Cambridge University.
Metabolomics is the key to understanding biology, health, wellness and disease. All biological systems, including humans, are continually fueling a collection of chemical reactions. At its core, metabolomics is the large-scale study of small molecules, called metabolites, that comprise the metabolome. The science provides an assessment of health, whether influenced by genes, the environment, epigenetics or the microbiome. As innovation in other life sciences areas has slowed, metabolomics is proving to be the next frontier in supporting companies in their understanding of data revealing state of health and the influences of genes, microbiome, diet, lifestyle and drug treatment.
About Metabolon, Inc.
Metabolon, Inc., is the global leader in revealing new biological insights through metabolomics, harnessing the power of its Precision Metabolomics™ Platform to provide biological insights of disease state and physiological reactions in the present time. The company offers scalable, customizable metabolomics solutions from discovery through clinical trials and product life-cycle management. Leveraging one of the world’s most diverse and rich patient data sets, Metabolon is equipped to deliver biologically relevant insights to address some of the most difficult and pressing questions in the life sciences, helping to accelerate research and product development success in the biopharma, population health, consumer products, wellness and academic research sectors. For more information, please visit www.metabolon.com or follow us on LinkedIn or Twitter.
# # #
Elizabeth Romero, Manager, Marketing Communications, Metabolon, Inc., Mobile: 954-461-7648, email@example.com